| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787534 | Journal of Thoracic Oncology | 2018 | 8 Pages |
Abstract
Pembrolizumab's lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression â¥50%, suggests that it is not an appropriate therapeutic choice in this setting.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. MD, A. MD, J.W. MD, K. BS, N. MD, T. MD, P. MD, B. MSN NP, M. MSN NP, J. BS, B. BS, B. BS, J. BS, J. BS, M. BS, J. BS, J. BS, T. BS, Edward B. MD, MS,